March 28, 2013 – Shire, a specialty biopharmaceutical company, is currently in clinical trials with a new iron chelator. Below, Shire responds to questions from CAF concerning the status of the drug, currently known as SPD602. How did Shire become interested in SPD602? In April 2012, Shire acquired FerroKin BioSiences, Inc. and the iron chelator […]
March 23, 2013 – The Thalassaemia International Federation (TIF) has announced that it will be awarding a limited number of sponsorships to the 15th International Conference for Patients and Parents in Abu Dhubai on October 22-23, 2013. Applications for these sponsorships must be submitted by May 15. Eligibility requirements and further information can be downloaded […]
March 6, 2013 – Gargi Pahuja, a valued and respected leader in the thalassemia community who passed away last summer, will be honored as Volunteer of the Year by America’s Blood Centers at the organization’s Annual Awards of Excellence Banquet on March 18. Gargi, who was a long time member of the CAF Board, a […]
February 22, 2013 – Funding for the National Institutes of Health (NIH) is in serious jeopardy. Without congressional action, NIH will receive a $1.6 billion cut when sequestration begins on Friday, March 1. It is critical that all Representatives and Senators hear from patients about the impact that inadequate funding has on the development of […]
January 6, 2013 – Registration for CAF’s Care Walk 2013 is now open! Sign up today to participate in the May 5 event by clicking here! Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Rather than hold one huge […]
February 11, 2013 – The Centers for Disease Control and Prevention (CDC) will present a special Facebook Chat on “Blood Disorders & the 3 P’s (Preconception, Pregnancy, & the Postpartum Period): What Every Woman Needs to Know” on Thursday, March 7, 2013, from 12:00 noon – 1:00 p.m. (Eastern Time). Women with blood disorders face […]
January 28, 2013 – CAF is pleased to share the information from selected presentations from the 2012 CAF Patient~Family Conference. We are posting here the presentation on “Iron Levels: How Low Can You Go?” More videos will be posted as they become available. Stay tuned for information on the 2013 Patient~Family Conference. It will be […]
January 28, 2013 – Acceleron, a biopharmaceutical company based in Cambridge, Massahusetts, in collaboration with Summit, New Jersey-based pharmaceutical partner Celgene Corporation, is developing two programs, sotatercept (formerly called ACE-011) and ACE-536, for the treatment of beta-thalassemia. Sotatercept and ACE-536 are biologic drugs that increase hemoglobin and red blood cells levels by promoting the maturation […]
January 23, 2013 – From an FDA press release: The U.S. Food and Drug Administration today expanded the approved use of Exjade (deferasirox) to treat patients ages 10 years and older who have chronic iron overload resulting from a genetic blood disorder called non-transfusion-dependent thalassemia (NTDT). NTDT is a milder form of thalassemia that does […]
January 23, 2013 – Aaron Cheng, a sophomore at Harvard University who has beta thalassemia major, has been awarded a 2012 Scholarship Award from the Asian Pacific Community Fund in association with Verizon. He is one of five recipients in this awards cycle. The Asian Pacific Community Fund partners with Verizon to financially assist students […]
